Melasma treatment ladder by evidence

Melasma is one of the most common pigment disorders worldwide and one of the most frustrating to treat. Brown or gray-brown patches appear symmetrically on the cheeks, forehead, nose, upper lip, and jaw. They darken with sun exposure, hormonal shifts, and heat. They fade partially with treatment, then recur. No cure exists. The goal of treatment is control — reducing pigment to a level the patient can maintain with ongoing discipline.

This article walks through the treatment options in order of evidence strength, from the non-negotiable foundation (sun protection) through topical agents, oral medications, chemical peels, and energy-based devices. Each step explains what it does, what the evidence supports, and what the limitations are. The goal is not to recommend a single protocol — that requires a clinician who can evaluate skin type, melasma depth, and medical history — but to give patients and providers a structured reference for making those decisions.

What melasma is (and is not)

Melasma is an acquired hyperpigmentation disorder driven by overactive melanocytes — the pigment-producing cells in the skin. It is not a sun spot, not a freckle, and not post-inflammatory hyperpigmentation (PIH), though it can coexist with all three.

Three subtypes are recognized based on depth:

• Epidermal: pigment is in the upper layer of skin. Appears brown with sharp borders. Responds better to treatment. Visible under Wood's lamp.
• Dermal: pigment has dropped into the deeper layer. Appears gray-blue with blurred borders. More resistant to treatment. Less visible under Wood's lamp.
• Mixed: both layers are involved. The most common presentation.

Triggers include UV exposure, visible light, hormonal changes (pregnancy, oral contraceptives, hormone replacement therapy), thyroid disease, and genetic predisposition. Melasma is far more common in women (9:1 ratio) and in people with Fitzpatrick skin types III–V (darker Caucasian, Hispanic, Asian, and Middle Eastern skin). It is also more prevalent in regions with high UV index.

Step 1: Sun protection (non-negotiable foundation)

Sun protection is not optional in melasma management. It is the base of the ladder. Without it, every other treatment will underperform or fail.

What the evidence says: UV radiation and visible light both stimulate melanocytes. A 2020 review in the Journal of the American Academy of Dermatology found that broad-spectrum SPF 50 sunscreen alone produces measurable improvement in melasma over 12 weeks — before any active treatment is added.

Iron-oxide tinted sunscreen is critical. Standard SPF formulations block UV but not visible light. Visible light (particularly blue light, 400–500 nm) independently triggers melanogenesis in melasma-prone skin. Iron oxide pigments in tinted sunscreens absorb visible light. A randomized trial comparing SPF 50+ sunscreen with and without iron oxide found that the iron-oxide formulation produced an additional 15% improvement in melasma severity scores. Dermatologist Dr. Sebastian Podlipnik's 2026 treatment guide describes tinted SPF with iron oxide as providing "mandatory base" protection.

Practical guidance:

• SPF 50+ broad-spectrum sunscreen, applied generously (2 mg/cm²) and reapplied every 2 hours during exposure.
• Tinted formulation with iron oxide for visible-light protection.
• Physical barriers: wide-brimmed hat, seeking shade, avoiding peak UV hours.
• Year-round, 365 days. Melasma does not take winters off.

Step 2: Triple combination topical cream (first active line)

The gold standard first-line treatment is a triple combination cream containing hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%. This is the formulation in Tri-Luma (Galderma), the only FDA-approved topical treatment specifically indicated for melasma.

FDA status: Tri-Luma Cream (fluocinolone acetonide 0.01% / hydroquinone 4% / tretinoin 0.05%) is FDA-approved for the short-term (up to 8 weeks) treatment of moderate to severe facial melasma.

What each ingredient does:

• Hydroquinone 4% inhibits tyrosinase, the enzyme that drives melanin production. It is the most studied depigmenting agent and has the strongest evidence base for melasma.
• Tretinoin 0.05% increases epidermal cell turnover, which helps shed pigmented keratinocytes faster. It also enhances penetration of hydroquinone and prevents the corticosteroid component from causing skin atrophy.
• Fluocinolone acetonide 0.01% is a low-potency topical corticosteroid that reduces inflammation. Since melanocytes are activated by inflammatory signals, reducing inflammation helps break the cycle of pigment production.

What the evidence says: In the pivotal phase 3 trials that led to FDA approval (641 patients, Fitzpatrick I–IV), 77% of Tri-Luma subjects experienced complete or near-complete clearing of facial melasma by week 8. The triple combination was significantly more effective than any two-ingredient combination. A 2026 meta-analysis by Chua et al. found that triple combination cream outperformed picosecond laser (755 nm alexandrite) for melasma reduction, and that the odds of new pigment appearing as a reaction to treatment were almost 7× higher with the laser than with the cream.

Limitations:

• Hydroquinone cannot be used indefinitely. Most dermatologists limit continuous use to 3–6 months, then recommend a break (often switching to non-HQ maintenance agents). Long-term HQ use carries risks of paradoxical darkening (ochronosis) and irritation.
• Tri-Luma is specifically approved for short-term use (up to 8 weeks). A 12-month study by Torok et al. demonstrated safety with intermittent use, but continuous long-term use requires monitoring.
• The tretinoin component causes dryness, peeling, and irritation in many patients, especially in the first 2–4 weeks. This needs to be anticipated and managed with moisturizers.
• Hydroquinone is contraindicated in pregnancy.

Alternatives for patients who cannot use hydroquinone:

• Azelaic acid 15–20% (prescription): inhibits tyrosinase and is safe in pregnancy. Less potent than HQ but well-tolerated for long-term use.
• Thiamidol: a synthetic tyrosinase inhibitor identified as one of the most potent human tyrosinase inhibitors in laboratory testing. Available in OTC formulations (notably Eucerin Anti-Pigment). A 2025 study found 0.5% thiamidol comparable to 4% hydroquinone with better tolerability. Growing evidence base supports its use for both treatment and maintenance. Particularly relevant in European protocols where some clinicians now prefer thiamidol over hydroquinone for long-term use.
• Cysteamine cream: emerging evidence as a non-HQ alternative that reduces melanin synthesis through antioxidant activity and tyrosinase inhibition.
• 2-MNG: a newer depigmenting agent that inhibits melanin synthesis downstream without directly blocking tyrosinase. 2025 studies found 0.5% 2-MNG non-inferior to 4% hydroquinone, with better tolerability. Still early in clinical adoption.
• Kojic acid: a tyrosinase inhibitor derived from fungi. Available in OTC and prescription formulations. Less evidence than HQ.
• Tranexamic acid topical (2–5%): weaker evidence than oral TXA, but some studies show benefit as an adjunct. A 2025 RCT by Heidary et al. found that both oral and topical TXA produced significant improvement, though oral outperformed topical.

Step 3: Oral tranexamic acid

Tranexamic acid (TXA) is an antifibrinolytic medication traditionally used to prevent excessive bleeding. In dermatology, it has emerged as one of the most promising systemic treatments for melasma.

Mechanism: TXA inhibits the conversion of plasminogen to plasmin. Plasmin stimulates melanocyte activity through inflammatory mediators. By blocking this pathway, TXA reduces melanin production. The mechanism is both anti-inflammatory and antioxidant.

What the evidence says: A 2025 randomized clinical trial by Heidary et al. compared oral TXA vs topical TXA for melasma treatment. Both groups showed significant improvement in MASI scores, with oral TXA producing greater reduction. A 2018 review by Bala et al. in Dermatologic Surgery summarized multiple trials of oral TXA for melasma, with individual studies reporting MASI reductions of approximately 49–65% at doses of 250 mg twice daily for 12 weeks. The 2025 PMC review on emerging melasma treatments describes TXA as having "the best evidence" among systemic treatments.

Dosing: Typical protocols use 250 mg orally twice daily for 3–6 months. Some clinicians use lower doses (250 mg once daily) for maintenance after initial improvement.

Safety considerations:

• TXA is a thrombophilic drug. It should not be used in patients with a history of venous thromboembolism, coagulopathy, or increased thrombotic risk.
• Common side effects: gastrointestinal discomfort, menstrual changes (lighter periods).
• Must be prescribed and monitored by a physician. Over-the-counter use is not appropriate.

Evidence hierarchy: A 2026 consensus on evidence-based melasma strategies published in Dermatology Advisor gave high consensus support to oral TXA as a systemic adjunct or alternative when topicals are insufficient or not tolerated.

Step 4: Chemical peels (third-line adjunct)

Chemical peels are positioned as a third-line option — useful as adjuncts but not superior to topical therapy as monotherapy. The Dermatology Times review of the melasma treatment ladder specifically notes that "overall studies suggest that chemical peels do not have better melasma treatment outcomes than topical therapy."

Glycolic acid peels (20–70%): The most studied peels for melasma. A series of 4–6 peels every 2–4 weeks can accelerate pigment clearing when combined with topical therapy. Work by increasing epidermal turnover and disrupting melanin in the basal layer.

Trichloroacetic acid (TCA) peels (10–25%): Deeper peels that show efficacy for melasma but carry higher PIH risk, especially in Fitzpatrick IV–VI. Reserved for refractory cases.

Salicylic acid peels (20–30%): Lipophilic and anti-inflammatory; safer in darker skin types. Less evidence for melasma specifically but a reasonable option for patients with concurrent acne or oily skin.

Safety in skin of color: Peel depth must be carefully selected. Aggressive peels in Fitzpatrick IV–VI can trigger PIH that is harder to treat than the original melasma. Conservative concentrations, proper preparation with topical regimens, and strict sun protection post-peel are essential.

Step 5: Lasers and energy-based devices (for refractory cases)

Lasers are not first-line for melasma. They are reserved for cases that have not responded adequately to sun protection, topical therapy, and oral TXA. The reason: heat from lasers and light devices can trigger melanocyte activation, paradoxically worsening melasma or causing PIH — especially in darker skin types. The 2026 meta-analysis by Chua et al. found that triple combination cream was more effective than picosecond laser and had a lower risk of worsening pigment.

That said, certain laser protocols have evidence for melasma management:

Low-fluence Q-switched Nd:YAG (laser toning)

The most studied laser protocol for melasma. Uses the 1064 nm wavelength at very low fluence (sub-thermolytic) to fragment melanin particles without generating significant heat. A series of weekly or biweekly sessions can reduce pigmentation.

Evidence: The melasma treatment ladder published in Dermatology Times identifies low-fluence Q-switched Nd:YAG as "one of the best laser and light options for treating melasma, especially in darker types." However, repeated sessions carry a risk of rebound melasma — a paradoxical darkening that occurs in some patients after multiple treatments.

Picosecond lasers

755 nm alexandrite and 1064 nm Nd:YAG picosecond lasers deliver ultra-short pulses that fragment pigment with less thermal damage than Q-switched devices. Several studies show efficacy for melasma, but the 2026 meta-analysis found higher rates of new pigment development compared to topical therapy.

Key caveat: The 2026 meta-analysis (Chua et al.) found that triple combination cream outperformed picosecond laser for melasma reduction, and the chances of a new spot appearing as a reaction to the treatment itself were almost 7 times higher with the laser. This finding should be discussed with any patient considering laser for melasma.

Non-ablative fractional lasers (1927 nm)

Moxi (Sciton) and Clear + Brilliant Perméa (Solta) use the 1927 nm thulium wavelength, which targets water rather than melanin. This theoretically reduces the risk of melanocyte stimulation. Vingan et al. (2023) found reductions in dyspigmentation with the 1927 nm fractional laser, and the non-ablative mechanism carries lower PIH risk than ablative lasers.

Limitation: Results are modest and require multiple sessions. These devices are best positioned as maintenance tools in a comprehensive melasma protocol, not as standalone treatments.

Pulsed dye laser (PDL)

Some evidence suggests that the vascular component of melasma — increased blood vessels and vascular endothelial growth factor (VEGF) in melasma lesions — responds to PDL. This approach targets the vessels rather than the pigment directly. It may be particularly useful for the erythematous border around melasma patches.

IPL / BBL: use with extreme caution

Intense pulsed light (IPL) and broadband light (BBL) carry significant risk for melasma patients. The broad spectrum of light includes wavelengths that stimulate melanocytes, and the heat generated can trigger rebound pigmentation. IPL is generally not recommended for melasma unless performed by a very experienced provider with specific filter settings and conservative parameters — and even then, it is considered higher risk than the options above.

The melasma treatment ladder published in Dermatology Times explicitly positions IPL as a higher-risk option, and the melasma-laser-risk article on this site details why IPL can worsen melasma in skin of color.

Putting it together: a structured approach

The treatment ladder, synthesized from the 2019 Dermatology Times review by Spierings, the 2022 PMC update on melasma treatment, and the 2026 consensus on evidence-based strategies:

What melasma patients should ask their dermatologist

1. What type of melasma do I have — epidermal, dermal, or mixed? This changes prognosis and treatment selection. A Wood's lamp examination can help determine depth.

2. What is the plan for long-term maintenance after the initial treatment? Melasma recurs. The initial treatment is not the hard part — the maintenance phase is. Ask what the 12-month plan looks like.

3. Am I a candidate for oral tranexamic acid? If topicals are not enough, oral TXA has strong evidence. But it requires screening for thrombotic risk.

4. What are the risks of laser for my skin type? If you have Fitzpatrick IV–VI skin, the risk of PIH and rebound melasma from laser is higher. This should be discussed explicitly.

5. How long should I use hydroquinone? Most dermatologists recommend cycling off HQ after 3–6 months. Ask what the transition plan looks like and what will maintain your results during the break.

Sources

• Tri-Luma Cream prescribing information (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%). FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021112s009lbl.pdf
• McKesey J, Tovar-Garza A, Pandya AG. Melasma treatment: an evidence-based review. Am J Clin Dermatol. 2020;21(2):173–225.
• Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M. Oral tranexamic acid for the treatment of melasma: a review. Dermatol Surg. 2018;44(6):814–825.
• Heidary B, et al. Randomized clinical trial on the efficacy of oral tranexamic acid versus topical tranexamic acid in treatment of melasma. J Cosmet Dermatol. 2025;24(9):e70428. https://pmc.ncbi.nlm.nih.gov/articles/PMC12418907
• Torok HM, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis. 2005;75(1):57-62.
• Spierings NMH. Evidence-based update on melasma. Dermatology Times, November 2019.
• Chua et al. 2026 meta-analysis: triple combination cream vs picosecond laser for melasma. Referenced in Podlipnik S. Melasma treatment guide 2026. https://www.sebastianpodlipnik.com/en/melasma-treatment
• Update on melasma — Part II: Treatment. https://pmc.ncbi.nlm.nih.gov/articles/PMC9464276
• Targeting melasma: innovations in pigment deposition and photoaging. https://pmc.ncbi.nlm.nih.gov/articles/PMC12783984
• Consensus on evidence-based strategies for melasma management. Dermatology Advisor, 2026.
• Vingan NR, Panton JA, Barillas J, et al. Investigating the efficacy of a fractionated 1927 nm laser for diffuse dyspigmentation and actinic changes. Lasers Surg Med. 2023;55(4):344-358.